UBS has revised its price target for Regeneron (REGN, Financial) to $584, a slight increase from the previous target of $560, while maintaining a Neutral rating on the stock. This adjustment reflects the firm's positive outlook for Regeneron's Eylea franchise, with expectations for the second quarter financials slightly exceeding the general market consensus by 2%. UBS considers the current stock valuation to adequately balance the potential risks and rewards in the near term.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.